Drug Trial Radar · NCT04315792
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Last checked: Nov 19, 2026Latest source record: Sep 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Aug 3, 2020
Primary completion
Jan 25, 2021
Study completion Aug 25, 2021
Sponsor
- Lead sponsor
- Jina Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novum Pharmaceutical Research Services; Lambda Therapeutic Research Ltd.
- First posted
- Mar 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the study population. As endoxifen represents a totally new class of drugs in the treatment of the bipolar disorder, it is essential to compare the drug against placebo to rule out the psychological influence upon study results. More so given the risks to patients and their communities from a medication whose efficacy has not been thoroughly evaluated against a placebo control. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products.
Conditions
- Bipolar I Disorder
Interventions
EndoxifenDrug
Administration of Endoxifen for 3 weeks
Placebo oral tabletDrug
Administration of Placebo for 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the efficacy and establish superiority of endoxifen 8 mg against placebo in Bipolar I Disorder patients (Mean change in total YMRS score)Time frame: 3 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
16420 NW 59 Avenue
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.